jetcityimage
jetcityimage / iStockphoto.com
27 July 2017Americas

GSK cuts down on R&D projects; Eli Lilly to update oncology strategy

GSK has revealed plans to cut back on research and development (R&D), while Eli Lilly announced a plan to focus its R&D resources on oncology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

More on this story

Big Pharma
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.

More on this story

Big Pharma
7 June 2018   GSK has confirmed that its $13 billion buyout of Novartis from the companies’ consumer healthcare joint venture has been completed following approval from shareholders.